The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Pemetrexed versus docetaxel in non-small cell lung cancer
Author(s): 
Pages: 1227-1229
Year: Issue:  12
Journal: The Chinese Journal of Clinical Pharmacology

Keyword:  pemetrexedcisplatinnon-small cell lung cancerthioredoxin-interacting proteinneoadjuvant chemotherapy;
Abstract: Objective To investigate the clinical efficacy and safety profile of pemetrexed/docetaxel in combination with cisplatin neoadjuvant chemotherapy in non-small cell lung cancer(NSCLC) patients.Methods A total of 60 patients with NSCLC were assigned to treatment group(n = 33) and control group(n = 27) according to different chemotherapy regimens.Control group received intravenous drip of docetaxel(75 mg·m-2,Day 1) combined with cisplatin(25 mg·m-2,Day 1-3); Treatment group received intravenous drip of pemetrexed(500 mg·m-2,Day 1) combined with cisplatin(25 mg·m-2,Day 1-3);Both groups were treated for 2 cycles(a cycle = 21 days,with 1 week interval between each chemotherapy cycle).The clinical efficacy,expression of thioredoxin binding protein(TXNIP) and adverse drug reactions were compared between 2 groups.Results The median progression-free survival time were 7.2 months and 4.9 months in treatment group and control group, respectively, with significant difference(P < 0.05).There were statistically significant differences in the relative expression of TXNIP between the lung tissue of treatment group and control group(1.12 ± 0.01 vs 0.32 ± 0.01)(P < 0.01).There were statistically significance between the two groups in main adverse drug reactions,including eucopenia,hemoglobin reduction,thrombocytopenia,nausea and vomiting,rash,and liver function damage(P < 0.05).Conclusion Pemetrexed in combination with cisplatin exerted considerable clinical efficacy and safety profile in the treatment of NSCLC by increasing the expression of TXNIP in lung tissue.
Related Articles
loading...